

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_84689
Title of the Manuscript:	Nafamostat mesylate in the prevention of post-endoscopic retrograde cholangiography pancreatitis: A meta-analysis
Type of the Article	Review Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journaljpri.com/index.php/JPRI/editorial-policy>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	Though authors state in the first sentence in the "Abstract" that NM was found effective, how was it regarded as effective in the absence of well-controlled randomized trials? Exact overall criterion of effectiveness of the drug should be specified. Exact protocol should be prescribed concerning the dose and route and timing of administration of the drug. Demographic of the patients should be presented.	
<u>Minor</u> REVISION comments		
<u>Optional/General</u> comments	Lines 1-3 in "Eligibility Criteria" do not make sense and there are other ungrammatical sentences.	

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i><u>(If yes, Kindly please write down the ethical issues here in details)</u></i>	

Reviewer Details:

Name:	Kenji Sasaki
Department, University & Country	Midtown Medicare Clinic, Japan